Mangalam Drugs Faces Going Concern Risk Amid Q2 Loss

Net Loss: Rs 7.21 crore | Revenue: Rs 79.39 crore

Reader Takeaway: Rising revenue fails to mask severe debt-driven insolvency risks and ongoing SARFAESI recovery proceedings from consortium lenders.

What just happened

Mangalam Drugs & Organics Ltd released its unaudited results for the quarter ended September 30, 2026. While the company posted revenue of Rs 79.39 crore, up from Rs 49.26 crore in the same period last year, it continued to bleed cash with a net loss of Rs 7.21 crore. More critically, the statutory auditor has issued an 'Emphasis of Matter' paragraph, explicitly noting that material uncertainties exist regarding the company's ability to continue as a going concern.

Why this matters

The company is under extreme financial distress due to the classification of its borrowings from Bank of Maharashtra and Bank of Baroda as Non-Performing Assets (NPAs). These accounts have exceeded sanctioned limits since October 2025. Total outstanding dues to these lenders have reached Rs 55.57 crore. Bank of Baroda has already served a demand notice under Section 13(2) of the SARFAESI Act for Rs 26.72 crore, placing the company’s assets at risk of seizure.

The liquidity crunch

The company's balance sheet reflects a deep structural imbalance. Current liabilities now exceed current assets by Rs 45.21 crore. Despite these red flags, management continues to prepare financial statements on a going-concern basis, pinning hopes on ongoing debt-resolution discussions and a reported net worth of Rs 88.28 crore. However, the auditor’s formal notation serves as a stark warning to shareholders regarding the sustainability of current operations.

What to track next

Investors should closely monitor the outcome of the SARFAESI proceedings and any potential settlement or restructuring agreement with the lender consortium. The resolution of the Rs 55.57 crore debt pile is the primary determinant of the firm's future viability.